25 1 form25.htm 25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-40388

ANEBULO PHARMACEUTICALS, INC.

Exchange: The Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Anebulo Pharmaceuticals, Inc.

1017 Ranch Road 620 South, Suite 107

Lakeway, TX 78734

(512) 598-0931

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, $0.001 par value per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

	☐	17 CFR 240.12d2-2(a)(1)

	☐	17 CFR 240.12d2-2(a)(2)

	☐	17 CFR 240.12d2-2(a)(3)

	☐	17 CFR 240.12d2-2(a)(4)

	☐	Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

	☒	Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Anebulo Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25, and has caused this notice to be signed on its behalf by the undersigned duly authorized person.

	Anebulo Pharmaceuticals, Inc.

Date: February 17, 2026	By:	/s/ Richard Anthony Cunningham
	Name:	Richard Anthony Cunningham
	Title:	Chief Executive Officer and Interim Chief Financial Officer

SEC Form 25 filed by Anebulo Pharmaceuticals Inc.